A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change

@article{Daly2015APS,
  title={A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change},
  author={Bobby Daly and Olufunmilayo I. Olopade},
  journal={CA: A Cancer Journal for Clinicians},
  year={2015},
  volume={65}
}
It is well known that there is a significant racial divide in breast cancer incidence and mortality rates. African American women are less likely to be diagnosed with breast cancer than white women but are more likely to die from it. This review explores the factors that may contribute to the racial survival disparity. Consideration is paid to what is known about the role of differences in tumor biology, genomics, cancer screening, and quality of cancer care. It is argued that it is the… 

An overview of cancer health disparities: new approaches and insights and why they matter

This review will discuss unanswered questions and new opportunities in cancer health disparity research related to comorbid chronic diseases, stress signaling, the immune response, and the microbiome, and what contribution these factors may have as causes of cancer health disparities.

Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real‐world data

Records from the Maryland Cancer Registry were analyzed to investigate the impact of CVD on disparities in mortality and comment on methodological considerations in this investigation and some important next steps for unraveling how these disparities in cardiovascular mortality arise after breast cancer treatment.

Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer

Advances in HBC diagnosis and treatment without widespread implementation have the potential to further widen the existing breast cancer mortality gap between Black and NHW women.

Racial and Ethnic Disparities in Breast Cancer: A Collaboration Between the American College of Radiology Commissions on Women and Diversity and Breast Imaging

Increased awareness and targeted efforts to identify and mitigate all of the underlying causes of breast cancer disparities will be necessary to realize the maximum benefit of screening, diagnosis, and treatment and to optimize quality of life and mortality gains for all women.

Racial disparities in survival outcomes among breast cancer patients by molecular subtypes

It is confirmed that racial disparity existed between White and Black breast cancer patients in terms of both survival and recurrence, and found that this disparity was largest among HR−/her2+ and HR+/HER2− patients.

Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities

Although blacks continue to have higher cancer death rates than whites, the disparity has narrowed and the racial gap in death rates has widened for all cancers combined in men and women and for lung and prostate cancers in men.

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer.

Health systems and individual providers should focus on improving communication about the importance of ET use, sharing decisions around ET, providing appropriate support for side effects and other ET-related concerns, and equitably delivering survivorship care, including ET adherence assessment.

An Expanded Agenda for the Primary Prevention of Breast Cancer: Charting a Course for the Future

The structured, innovative approach used by BCPP to integrate scientific evidence with community perspectives provides a model for other states to consider, to potentially change the future trajectory of breast cancer incidence in the United States.

Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women

It was found that the time between diagnosis and treatment onset was longer for African Americans — 62 days compared to 35.5 days for white women and overall survival probability was significantly associated with race.

Racial disparities in triple negative breast cancer: toward a causal architecture approach

The use of ICE can facilitate the monitoring of cancer inequities and advance the study of racial disparities in breast cancer.
...

References

SHOWING 1-10 OF 150 REFERENCES

Breast cancer racial disparities: unanswered questions.

A comprehensive overview of the literature on racial disparities in breast cancer outcome is presented and potential causative factors that may contribute to disparities seen among blacks and whites with breast cancer are highlighted.

American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities.

  • B. MoyB. Polite L. Newman
  • Medicine, Political Science
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Parts of the health care law relevant to cancer disparities are summarized and specific strategies to address insurance reform, access to care, quality of care, prevention and wellness, research on health care disparities, and diversity in the health Care workforce are outlined.

Race and subset analyses in clinical trials: time to get serious about data integration.

The authors conclude that the worse survival of black patients is likely because of factors unrelated to response to adjuvant treatment, such as racial differences in comorbidities, general life expectancy, or potentially in care for recurrent disease.

Missed opportunities: racial disparities in adjuvant breast cancer treatment.

Minority women with early-stage breast cancer have double the risk of white women for failing to receive necessary adjuvant treatments despite rates of oncologic consultation similar to those for white women.

Comorbidity and survival disparities among black and white patients with breast cancer.

Effective control of comorbidity in black breast cancer patients should help improve life expectancy and lead to a reduction in survival disparities.

Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients.

The findings suggest that hematologic tolerability of adjuvant chemotherapy is similar in black and white patients, and strategies aimed at improving psychosocial barriers to adjUvant therapy and at reducing surgical complications in black patients may improve overall breast cancer outcomes in this group.

Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.

Investigation of the relationship between race and the use of BRCA1/2 counseling among women with a family history of breast or ovarian cancer found racial disparities are large and do not appear to be explained by differences in risk factors for carrying a BRCa1/ 2 mutation, socioeconomic factors, risk perception, attitudes, or primary care physician recommendations.

Racial differences in genetic factors associated with breast cancer

Some of the genetic factors that have been shown to be associated with a difference in breast cancer outcome between African Americans and Caucasians in the US such as the BRCA1 and BRCa2 genes, p53 mutations, UGT1A1 gene polymorphisms, and HER-2/neu gene amplifications/overexpression are reviewed.

Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.

The proportion of breast cancers that were identified at an early stage (stage I) in different racial/ethnic groups was determined and whether ethnic differences may be better explained by early detection or by intrinsic biological differences in tumor aggressiveness.

A tracking and feedback registry to reduce racial disparities in breast cancer care.

A tracking and feedback registry that enhances completed oncology consultations between surgeons and oncologists also appears to reduce rates of adjuvant treatment underuse and to eliminate the racial disparity in treatment.
...